Enzo Biochem Stock Performance
| ENZ Stock | USD 1.04 0.03 2.80% |
The firm shows a Beta (market volatility) of 0.0337, which means not very significant fluctuations relative to the market. As returns on the market increase, Enzo Biochem's returns are expected to increase less than the market. However, during the bear market, the loss of holding Enzo Biochem is expected to be smaller as well. Enzo Biochem has an expected return of -0.3%. Please make sure to confirm Enzo Biochem value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Enzo Biochem performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Enzo Biochem has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in June 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 105:100 | Last Split Date 2004-10-21 |
1 | Global Clinical Biomarkers Market Set for Strong Growth, Forecast 2023-2033 Focus on Technologies and End Users | 02/16/2024 |
2 | Acquisition by Eckert Patricia of 75000 shares of Enzo Biochem at 1.38 subject to Rule 16b-3 | 02/23/2024 |
3 | Enzo Biochem, Inc. Short Interest Update - MarketBeat | 03/06/2024 |
4 | Enzo Biochem shareholders have endured a 69 percent loss from investing in the stock three years ago | 03/14/2024 |
5 | Acquisition by Kara Cannon of 345080 shares of Enzo Biochem subject to Rule 16b-3 | 03/25/2024 |
6 | Discretionary transaction by Wolf James G. of tradable shares of Enzo Biochem subject to Rule 16b-3 | 04/05/2024 |
7 | Acquisition by Wolf James G. of 444 shares of Enzo Biochem at 1.29 subject to Rule 16b-3 | 04/18/2024 |
8 | Global Clinical Biomarkers Industry Research, 2023-2024 2033 - Discovery of Novel Biomarkers Expanding Precision Medicine Horizons, Increase in Industrial Activ... | 04/29/2024 |
| Begin Period Cash Flow | 22.6 M | |
| Total Cashflows From Investing Activities | 99 M |
Enzo |
Enzo Biochem Relative Risk vs. Return Landscape
If you would invest 127.00 in Enzo Biochem on February 7, 2024 and sell it today you would lose (23.00) from holding Enzo Biochem or give up 18.11% of portfolio value over 90 days. Enzo Biochem is generating negative expected returns assuming volatility of 2.0237% on return distribution over 90 days investment horizon. In other words, 17% of stocks are less volatile than Enzo, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Enzo Biochem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enzo Biochem's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enzo Biochem, and traders can use it to determine the average amount a Enzo Biochem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1465
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ENZ |
Estimated Market Risk
| 2.02 actual daily | 17 83% of assets are more volatile |
Expected Return
| -0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Enzo Biochem is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enzo Biochem by adding Enzo Biochem to a well-diversified portfolio.
Enzo Biochem Fundamentals Growth
Enzo Stock prices reflect investors' perceptions of the future prospects and financial health of Enzo Biochem, and Enzo Biochem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enzo Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | 0.99 % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 1.75 M | ||||
| Shares Outstanding | 51.23 M | ||||
| Price To Earning | 26.60 X | ||||
| Price To Book | 0.85 X | ||||
| Price To Sales | 1.83 X | ||||
| Revenue | 31.06 M | ||||
| Gross Profit | 11.57 M | ||||
| EBITDA | (12.12 M) | ||||
| Net Income | 20.29 M | ||||
| Cash And Equivalents | 82.37 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 7 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 2.21 X | ||||
| Book Value Per Share | 1.40 X | ||||
| Cash Flow From Operations | (36.98 M) | ||||
| Earnings Per Share | (0.48) X | ||||
| Market Capitalization | 54.81 M | ||||
| Total Asset | 121.88 M | ||||
| Retained Earnings | (268.35 M) | ||||
| Working Capital | 58.47 M | ||||
| Current Asset | 91.4 M | ||||
| Current Liabilities | 20.57 M | ||||
About Enzo Biochem Performance
To evaluate Enzo Biochem Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Enzo Biochem generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Enzo Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Enzo Biochem market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Enzo's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 170.94 | 179.48 | |
| Return On Tangible Assets | 0.19 | 0.20 | |
| Return On Capital Employed | (0.35) | (0.33) | |
| Return On Assets | 0.19 | 0.20 | |
| Return On Equity | 0.23 | 0.24 |
Things to note about Enzo Biochem performance evaluation
Checking the ongoing alerts about Enzo Biochem for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enzo Biochem help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enzo Biochem generated a negative expected return over the last 90 days | |
| Enzo Biochem has some characteristics of a very speculative penny stock | |
| Enzo Biochem has about 82.37 M in cash with (36.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 24.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: Global Clinical Biomarkers Industry Research, 2023-2024 2033 - Discovery of Novel Biomarkers Expanding Precision Medicine Horizons, Increase in Industrial Activity in Clinical Biomarker Landscape - ResearchAndMarkets.com |
- Analyzing Enzo Biochem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enzo Biochem's stock is overvalued or undervalued compared to its peers.
- Examining Enzo Biochem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enzo Biochem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enzo Biochem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enzo Biochem's stock. These opinions can provide insight into Enzo Biochem's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enzo Biochem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Enzo Stock please use our How to Invest in Enzo Biochem guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Enzo Stock analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Enzo Biochem's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enzo Biochem. If investors know Enzo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enzo Biochem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.48) | Revenue Per Share 0.657 | Quarterly Revenue Growth 0.138 | Return On Assets (0.17) | Return On Equity (0.45) |
The market value of Enzo Biochem is measured differently than its book value, which is the value of Enzo that is recorded on the company's balance sheet. Investors also form their own opinion of Enzo Biochem's value that differs from its market value or its book value, called intrinsic value, which is Enzo Biochem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enzo Biochem's market value can be influenced by many factors that don't directly affect Enzo Biochem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enzo Biochem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enzo Biochem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enzo Biochem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.